Possible role of matriptase in the diagnosis of ovarian cancer

Expert Review of Molecular Diagnostics

Volumn 3, Issue 3, 2003, Pages 331-338

  Johnson, Michael D ^a   Oberst, Michael D ^b   Lin, Chen Yong ^c   Dickson, Robert B ^c  

^a GEORGETOWN UNIVERSITY   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Diagnosis; HAI 1; Matriptase; Ovarian cancer; Screening

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; HEPATOCYTE GROWTH FACTOR ACTIVATOR INHIBITOR 1; MATRIPTASE; MATRIPTASE INHIBITOR; SCATTER FACTOR RECEPTOR; SERINE PROTEINASE; SERINE PROTEINASE INHIBITOR; UNCLASSIFIED DRUG;

CANCER GROWTH; CANCER INHIBITION; DRUG EFFECT; DRUG MECHANISM; DRUG TARGETING; ENZYME ANALYSIS; ENZYME INHIBITION; ENZYME INHIBITOR INTERACTION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; INHIBITION KINETICS; NUCLEOTIDE SEQUENCE; OVARY CANCER; PATHOGENESIS; REVIEW;

DISEASE PROGRESSION; ENZYME ACTIVATION; FEMALE; HUMANS; OVARIAN NEOPLASMS; SERINE ENDOPEPTIDASES; SERINE PROTEINASE INHIBITORS; TRYPSIN; TUMOR MARKERS, BIOLOGICAL;

EID: 0038286370     PISSN: 14737159     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737159.3.3.331     Document Type: Review

References (66)

1. Young RC, Walton LA, Ellenberg SS et al. Adjuvant therapy in Stage I and Stage II epithelial ovarian cancer. Results of two prospective randomized trials. N. Engl. J. Med. 322, 1021-1027 (1990).
2. Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics, 1996. CA Cancer J. Clin. 46, 5-27 (1996).
3. Murdoch WJ, McDonnel AC. Roles of the ovarian surface epithelium in ovulation and carcinogenesis. Reproduction 123, 743-750 (2002). Ovarian surface epithelium injury and regrowth in ovarian carcinogenesis.
4. Gross TP, Schlesselman JJ. The estimated effect of oral contraceptive use on the cumulative risk of epithelial ovarian cancer. Obstet. Gynecol. 83, 419-424 (1994).
5. Whittemore AS. The risk of ovarian cancer after treatment for infertility. N. Engl. J. Med. 331, 805-806 (1994).
6. Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol. 2, 533-543 (2001).
7. Ozols RF, Schwartz PE, Eifel PG. Ovarian cancer, fallopian tube carcinoma and peritoneal carcinoma. In: Cancer: principles and practice of oncology. Devita VT, Hellman S, Rosenberg SA (Eds), Lippincott-Raven, NY, USA, 1502-1539 (1997).
8. Elit L. Familial ovarian cancer. Can. Fam. Physician 47, 778-784 (2001).
9. National Institutes of Health Consensus Development Conference Statement. Ovarian cancer: screening treatment and follow-up. Gynecol. Oncol. 55, S4-S14 (1994). Lack of utility of existing screening modalities for use on general population.
10. Olt GJ, Berchuck A, Bast RC Jr. Gynecologic tumor markers. Semin. Surg. Oncol. 6, 305-313 (1990).
11. Shi YE, Torri J, Yieh L, Wellstein A, Lippman ME, Dickson RB. Identification and characterization of a novel matrix-degrading protease from hormone-dependent human breast cancer cells. Cancer Res. 53, 1409-1415 (1993).
12. Lin CY, Wang JK, Torri J, Dou L, Sang QA, Dickson RB. Characterization of a novel, membrane-bound, 80-kDa matrix-degrading protease from human breast cancer cells: monoclonal antibody production, isolation and localization. J. Biol. Chem. 272, 9147-9152 (1997).
13. Lin CY, Anders J, Johnson M, Dickson RB. Purification and characterization of a complex containing matriptase and a Kunitz-type serine protease inhibitor from human milk. J. Biol. Chem. 274, 18237-18242 (1999).
14. Lin CY, Anders J, Johnson M, Sang QA, Dickson RB. Molecular cloning of cDNA for matriptase, a matrix-degrading serine protease with trypsin-like activity. J. Biol. Chem. 274, 18231-18236 (1999). Original cloning of matriptase.
15. Benaud C, Dickson RB, Lin CY. Regulation of the activity of matriptase on epithelial cell surfaces by a blood-derived factor. Eur. J. Biochem. 268, 1439-1447 (2001). Regulation of matriptase activity by phospholipids.
16. Benaud C, Oberst M, Hobson JP, Spiegel S, Dickson RB, Lin CY, Sphingosine 1-phosphate, present in serum-derived lipoproteins, activates matriptase. J. Biol. Chem. 277, 10539-10546 (2002).
17. Zhang Y, Cai X, Schlegelberger B, Zheng S. Assignment 1 of human putative tumor suppressor genes ST13 (alias SNC6) and ST14 (alias SNC19) to human chromosome bands 22q13 and 11q24->q25 by in situ hybridization. Cytogenet. Cell Genet. 83, 56-57 (1998).
18. Takeuchi T, Shuman MA, Craik CS. Reverse biochemistry: use of macromolecular protease inhibitors to dissect complex biological processes and identify a membrane-type serine protease in epithelial cancer and normal tissue. Proc. Natl Acad. Sci. USA 96, 11054-11061 (1999).
19. Tanimoto H, Underwood LJ, Wang Y, Shigemasa K, Parmley TH, O'Brien TJ. Ovarian tumor cells express a transmembrane serine protease: a potential candidate for early diagnosis and therapeutic intervention. Tumour Biol. 22, 104-114 (2001). Identification of matriptase as protein differentially regulated in ovarian cancer.
20. Kim MG, Chen C, Lyu MS et al. Cloning and chromosomal mapping of a gene isolated from thymic stromal cells encoding a new mouse Type II membrane serine protease, epithin, containing four LDL receptor modules and two CUB domains. Immunogenetics 49, 420-428 (1999).
21. Satomi S, Yamasaki Y, Tsuzuki S, Hitomi Y, Iwanaga T, Fushiki T. A role for membrane-type serine protease (MT-SP1) in intestinal epithelial turnover. Biochem. Biophys. Res. Commun. 287, 995-1002 (2001).
22. Kishi K, Yamazaki K, Yasuda I et al. Characterization of a membrane-bound arginine-specific serine protease from rat intestinal mucosa. J. Biochem. 130, 425-430 (2001).
23. Yamada K, Takabatake T, Takeshima K. Isolation and characterization of three novel serine protease genes from Xenopus laevis. Gene 252, 209-216 (2000).
24. Appel LF, Prout M, Abu-Shumays R et al. The Drosophila Stubble-stubbloid gene encodes an apparent transmembrane serine protease required for epithelial morphogenesis. Proc. Natl Acad. Sci. USA 90, 4937-4941 (1993).
25. Cho EG, Kim MG, Kim C et al. N-terminal processing is essential for release of epithin, a mouse Type II membrane serine protease. J. Biol. Chem. 276, 44581-44589 (2001).
26. Oberst M, Anders J, Xie B et al. Matriptase and HAI-1 are expressed by normal and malignant epithelial cells in vitro and in vivo. Am. J. Pathol. 158, 1301-1311 (2001).
27. Thielens NM, Bersch B, Hernandez JF, Arlaud GJ. Structure and functions of the interaction domains of C1r and C1s: keystones of the architecture of the C1 complex. Immunopharmacology 42, 3-13 (1999).
28. Hooper JD, Clements JA, Quigley JP, Antalis TM. Type II transmembrane serine proteases. Insights into an emerging class of cell surface proteolytic enzymes. J. Biol. Chem. 276, 857-860 (2001).
29. Velasco G, Cal S, Quesada V, Sanchez LM, Lopez-Otin C. Matriptase-2, a membrane-bound mosaic serine proteinase predominantly expressed in human liver and showing degrading activity against extracellular matrix proteins. J. Biol. Chem. 277, 37637-37646 (2002).
30. Friedrich R, Fuentes-Prior P, Ong E et al. Catalytic domain structures of MT-SP1/matriptase, a matrix-degrading transmembrane serine proteinase. J. Biol. Chem. 277, 2160-2168 (2002).
31. Kataoka H, Suganuma T, Shimomura T et al. Distribution of hepatocyte growth factor activator inhibitor Type 1 (HAI-1) in human tissues. Cellular surface localization of HAI-1 in simple colunmar epithelium and its modulated expression in injured and regenerative tissues. J. Histochem. Cytochem. 47, 673-682 (1999).
32. Payne SG, Milstien S, Spiegel S. Sphingosine-1-phosphate: dual messenger functions. FEBS Lett. 531, 54-57 (2002).
33. Benaud CM, Oberst M, Dickson RB, Lin CY. Deregulated activation of matriptase in breast cancer cells. Clin. Exp. Metastasis 19, 639-649 (2002).
34. Takeuchi T, Harris JL, Huang W, Yan KW, Coughlin SR, Craik CS. Cellular localization of membrane-type serine protease 1 and identification of protease-activated receptor 2 and single-chain urokinase-type plasminogen activator as substrates. J. Biol. Chem. 275, 26333-26342 (2000). Identification of urokinase plasminogen activator (uPA) and protease-activated receptor-2 as matriptase substrates.
35. Lee SL, Dickson RB, Lin CY. Activation of hepatocyte growth factor and urokinase/plasminogen activator by matriptase, an epithelial membrane serine protease. J. Biol. Chem. 275, 36720-36725 (2000). Idenfification of hepatocyte growth factor and uPA as matriptase substrates.
36. Oberst MD, Johnson MD, Dickson RB et al. Expression of the serine protease matriptase and its inhibitor HAI-1 in epithelial ovarian cancer: correlation with clinical outcome and tumor dinicopathological parameters. Clin. Cancer Res. 8, 1101-1107 (2002). Hepatocyte growth factor activator inhibitor-1 expression is much less common in more advanced ovarian tumors suggesting that HAI-1 may be lost during tumor progression resulting in increased matriptase activity in these tumors.
37. Suzuki M, Kobayashi H, Tanaka Y et al. Bikunin target genes in ovarian cancer cells identified by microarray analysis. J. Biol. Chem. (2003) (In Press).
38. Pujade-Lauraine E, Lu H, Mirshahi S et al. The plasminogen-activation system in ovarian tumors. Int. J. Cancer 55, 27-31 (1993).
39. van der Burg ME, Henzen-Logmans SC, Berns EM, van Putten WL, Klijn JG, Foekens JA. Expression of urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in benign, borderline, malignant primary and metastatic ovarian tumors. Int. J. Cancer 69, 475-479 (1996).
40. Konecny G, Untch M, Pihan A et al. Association of urokinase-type plasminogen activator and its inhibitor with disease progression and prognosis in ovarian cancer. Clin. Cancer Res. 7, 1743-1749 (2001).
41. Schmalfeldt B, Prechtd D, Harting K et al. Increased expression of matrix metalloproteinases (MMP)-2, MMP-9 and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer. Clin. Cancer Res. 7, 2396-2404 (2001).
42. Borgfeldt C, Hansson SR, Gustavsson B, Masback A, Casslen B. Dedifferentiation of serous ovarian cancer from cystic to solid tumors is associated with increased expression of mRNA for urokinase plasminogen activator (uPA), its receptor (uPAR) and its inhibitor (PAI-1). Int. J. Cancer 92, 497-502 (2001).
43. Kuhn W, Schmalfeldt B, Reuning U et al. Prognostic significance of urokinase (uPA) and its inhibitor PAI-1 for survival in advanced ovarian carcinoma stage FIGO IIIc. Br. J. Cancer 79, 1746-1751 (1999).
44. Chambers SK, Ivins CM, Carcangiu ML. Plasminogen activator inhibitor-1 is an independent poor prognostic factor for survival in advanced stage epithelial ovarian cancer patients. Int. J. Cancer 79, 449-454 (1998).
45. Chambers SK, Gertz RE Jr, Ivins CM, Kacinski BM. The significance of urokinase-type plasminogen activator, its inhibitors and its receptor in ascites of patients with epithelial ovarian cancer. Cancer 75, 1627-1633 (1995).
46. Wahlberg K, Hoyer-Hansen G, Casslen B. Soluble receptor for urokinase plasminogen activator in both full-length and a cleaved form is present in high concentration in cystic fluid from ovarian cancer. Cancer Res. 58, 3294-3298 (1998).
47. Riisbro R, Stephens RW, Brunner N et al. Soluble urokinase plasminogen activator receptor in preoperatively obtained plasma from patients with gynecological cancer or benign gynecological diseases. Gynecol. Oncol. 82, 523-531 (2001).
48. Naldini L, Tamagnone L, Vigna E et al. Extracellular proteolytic cleavage by urokinase is required for activation of hepatocyte growth factor/scatter factor. EMBO J. 11, 4825-4833 (1992).
49. Jeffers M, Rong S, Woude GE Hepatocyte growth factor/scatter factor - Met signaling in tumorigenicity and invasion/metastasis. J. Mol. Med. 74, 505-513 (1996).
50. Moghul A, Lin L, Beedle A et al. Modulation of c-MET proto-oncogene (HGF receptor) mRNA abundance by cytokines and hormones: evidence for rapid decay of the 8 kb c-MET transcript. Oncogene 9, 2045-2052 (1994).
51. Di Renzo MF, Olivero M, Katsaros D et al. Overexpression of the Met/HGF receptor in ovarian cancer. Int. J. Cancer 58, 658-662 (1994).
52. Huntsman D, Resau JH, Klineberg E, Auersperg N. Comparison of c-met expression in ovarian epithelial tumors and normal epithelia of the female reproductive tract by quantitative laser scan microscopy. Am. J. Pathol. 155, 343-348 (1999).
53. Parrott JA, Skinner MK. Expression and action of hepatocyte growth factor in human and bovine normal ovarian surface epithelium and ovarian cancer. Biol. Reprod. 62, 491-500 (2000).
54. Wong AS, Pelech SL, Woo MM et al. Coexpression of hepatocyte growth factor-Met: an early step in ovarian carcinogenesis? Oncogene 20, 1318-1328 (2001).
55. Corps AN, Sowter HM, Smith SK. Hepatocyte growth factor stimulates motility, chemotaxis and mitogenesis in ovarian carcinoma cells expressing high levels of c-met. Int. J. Cancer 73, 151-155 (1997).
56. Sowter HM, Corps AN, Evans AL, Clark DE, Charnock-Jones DS, Smith SK. Expression and localization of the vascular endothelial growth factor family in ovarian epithelial tumots. Lab. Invest. 77, 607-614 (1997).
57. Saga Y, Mizukami H, Suzuki M et al. Expression of HGF/NK4 in ovarian cancer cells suppresses intraperitoneal dissemination and extends host survival. Gene Ther. 8, 1450-1455 (2001).
58. Kang JY, Dolled-Filhart M, Ocal IT et al. Tissue microarray analysis of hepatocyte growth factor/Met pathway components reveals a role for Met, matriptase and hepatocyte growth factor activator inhibitor 1 in the progression of node-negative breast cancer. Cancer Res. 63, 1101-1105 (2003).
59. Xiao YJ, Schwartz B, Washington M et al. Electrospray ionization mass spectrometry analysis of lysophospholipids in human ascitic fluids: comparison of the lysophospholipid contents in malignant versus nonmalignant ascitic fluids. Anal. Biochem. 290, 302-313 (2001).
60. Westermann AM, Havik E, Postma FR et al. Malignant effusions contain lysophosphatidic acid (LPA)-like activity. Ann. Oncol. 9, 437-442 (1998).
61. Fang X, Gaudette D, Furui T et al. Lysophospholipid growth factors in the initiation, progression, metastases and management of ovarian cancer. Ann. NY Acad Sci. 905, 188-208 (2000).
62. Enyedy IJ, Lee SL, Kuo AH, Dickson RB, Lin CY, Wang S. Structure-based approach for the discovery of bis-benzamidines as novel inhibitors of matriptase. J. Med. Chem. 44, 1349-1355 (2001).
63. Long YQ, Lee SL, Lin CY et al. Synthesis and evaluation of the sunflower derived trypsin inhibitor as a potent inhibitor of the Type II transmembrane serine protease, matriptase. Bioorg. Med. Chem. Lett. 11, 2515-2519 (2001).
64. Kennedy AR. The Bowman-Birk inhibitor from soybeans as an anticarcinogenic agent. Am. J. Clin. Nutr. 68, 1406S-1412S (1998).
65. Meyskens FL. Development of Bowman-Birk inhibitor for chemoprevention of oral head and neck cancer. Ann. NY Acad. Sci. 952, 116-123 (2001).
66. Wan XS, Hamilton TC, Ware JH, Donahue JJ, Kennedy AR. Growth inhibition and cytotoxicity induced by Bowman-Birk inhibitor concentrate in cisplatin-resistant human ovarian cancer cells. Nutr. Cancer 31, 8-17 (1998).